35 POSTER A Phase I trial of a combination of the mToR Inhibitor Everolimus (RAD001) and two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in patients (pts) with advanced solid tumors
Year: 2006
Type: conference-abstract
Authors: G. Dy, G. Croghan, A. Furth, J. Reid, L. Hanson, M. Roos, A. Tan, A. Adjei
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2094800223